Bio/Pharmaceutical Outsourcing Report, July 2026

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2950
Buy Report Download FREE Resources

Published: August 25, 2026 Report Code: GDPB091-ST

Select Item

Track monthly trends in bio/pharmaceutical outsourcing, including CMO contracts, M&A, financing, facility investments, GMP inspections, opportunities, and industry risks.

Why Does Bio/Pharmaceutical Outsourcing Matter?

Bio/pharmaceutical outsourcing plays an important role in pharmaceutical manufacturing, with contract manufacturing organizations (CMOs) responding to changing demand, regulatory requirements, technology investment, and supply chain dynamics.

This monthly report provides analysis of the latest business conditions and developments affecting the pharmaceutical outsourcing industry. It tracks outsourcing contracts, CMO mergers and acquisitions, financing, facility openings and closures, GMP inspections, technology investments, supply chain challenges, and emerging opportunities and threats.

You can use this report to:

  • Monitor the latest developments in the pharmaceutical outsourcing industry
  • Track new outsourcing and contract service agreements
  • Identify opportunities and threats affecting CMOs
  • Assess recent M&A and financing activity
  • Monitor facility openings, closures, and investments
  • Track GMP inspections and inspection outcomes
  • Understand supply chain challenges and regulatory developments
  • Identify technology and equipment investment trends
  • Support supplier selection and management decisions
  • Strengthen competitor and market intelligence

Key Insights in the Bio/Pharmaceutical Outsourcing Landscape

The report highlights key developments affecting the pharmaceutical outsourcing industry, including:

  • Monthly analysis of business conditions affecting pharmaceutical CMOs
  • New bio/pharmaceutical outsourcing and contract service agreements
  • Recent CMO mergers and acquisitions
  • Financing activity within the manufacturing industry
  • Facility-level developments including planned site openings and closures
  • GMP inspections and inspection outcomes
  • Investments in manufacturing technology and equipment
  • Supply chain obstacles affecting pharmaceutical manufacturing
  • New regulations and their potential impact on manufacturers
  • Emerging opportunities and threats within contract manufacturing
  • Developments and innovations with potentially significant industry impact
  • Insights based on GlobalData databases covering deals, companies, drugs, financials, news, and clinical trials

Scope

What Will You Learn from This Bio/Pharmaceutical Outsourcing Report?

This report provides insight into:

  • Current trends in pharmaceutical outsourcing

  • Business conditions affecting CMOs

  • New outsourcing contracts and service agreements

  • CMO M&A activity

  • Manufacturing-sector financing deals

  • Facility openings and closures

  • Manufacturing facility investments

  • Technology and equipment investments

  • GMP inspections and outcomes

  • Supply chain challenges affecting manufacturers

  • Regulatory developments

  • Opportunities and threats within contract manufacturing

  • Emerging technologies and innovations

  • Developments affecting CMO competitiveness

  • Market and competitor intelligence relevant to pharmaceutical manufacturing

Who Should Buy This Bio/Pharmaceutical Outsourcing Report?

This report may be valuable for:

  • Contract manufacturing organizations

  • Bio/pharmaceutical manufacturers

  • Pharmaceutical companies

  • CMO executives

  • Strategic decision-makers

  • Sourcing and procurement executives

  • Supply chain teams

  • Business development teams

  • Corporate strategy teams

  • Investment firms and investors

  • Financial advisors

  • Management consultants

  • Industry and competitive intelligence teams

  • Regulatory and manufacturing professionals

  • Senior executives and decision-makers

How Companies Use This Bio/Pharmaceutical Outsourcing Analysis

CMOs, pharmaceutical companies, investors, and industry stakeholders can use the report to:

  • Monitor monthly developments in pharmaceutical outsourcing

  • Track new contract manufacturing agreements

  • Identify potential outsourcing opportunities

  • Assess threats affecting manufacturers and suppliers

  • Monitor CMO M&A and financing activity

  • Evaluate facility investment and expansion activity

  • Track facility openings and closures

  • Review GMP inspection outcomes

  • Monitor investments in manufacturing technology and equipment

  • Assess supply chain obstacles

  • Track new regulations affecting pharmaceutical manufacturing

  • Identify emerging technologies and industry developments

  • Support supplier selection and management

  • Strengthen competitor and market intelligence

  • Inform strategic planning and investment decisions

Reasons to Buy

Benchmark the Bio/Pharmaceutical Outsourcing Landscape

This report enables stakeholders to benchmark:

  • CMO outsourcing activity

  • New contract service agreements

  • M&A activity

  • Financing deals

  • Facility openings and closures

  • Manufacturing facility investments

  • Technology and equipment investments

  • GMP inspection activity and outcomes

  • Supply chain developments

  • Regulatory developments

  • Emerging opportunities and threats

  • Competitive developments across the CMO industry

Built on GlobalData Business Intelligence

The report combines GlobalData expert analysis with data from databases covering deals, companies, drugs, financials, news, and clinical trials.

Monthly coverage provides an up-to-date view of business conditions, outsourcing activity, facility-level developments, regulatory changes, manufacturing investments, and strategic developments affecting the pharmaceutical CMO landscape.

Act Now to Identify Opportunities in Bio/Pharmaceutical Outsourcing

As pharmaceutical manufacturers navigate changing supply chains, regulatory requirements, technology investment, and outsourcing demand, staying current on CMO developments can help companies identify emerging opportunities and potential risks.

Use this monthly report to track outsourcing contracts, M&A and financing, facility investments, GMP inspections, regulatory developments, and supply chain challenges, and to support strategic planning, supplier management, competitive intelligence, and investment decisions.

AGC Biologics Inc
AIM ImmunoTech Inc
Amneal Pharmaceuticals Inc
Ankyra Therapeutics Inc
Argonaut Manufacturing Services LLC
Avanti Polar Lipids Inc
BlueRock Therapeutics LP
Bora Biologics Co Ltd
BriaCell Therapeutics Corp
Cabaletta Bio Inc
Catalent Inc
Cellares Corp
Charles River Laboratories International Inc
Cynata Therapeutics Ltd
Dai Nippon Printing Co Ltd
Eli Lilly Group Limited
Ensera Inc
Evonik Industries AG
FUJIFILM Cellular Dynamics Inc
GC Green Cross Corp
GSK plc
Insilico Medicine
Intertek Group Plc
Intravacc BV
Jubilant HollisterStier LLC
KBI Biopharma Inc
Korea Vaccine Co Ltd
Kyowa Kirin Co Ltd
Lonza Group Ltd
Lotte Biologics Co Ltd
Lupin Ltd
Nitto Avecia Pharma Services Inc
NovoArc
Olpha
Patheon NV
PCI Pharma Services
Pharmaceutics International Inc
Prestige Biopharma Ltd
ProBioGen AG
Pyramid Laboratories Inc
Recipharm AB
Rottendorf Pharma GmbH
Samsung Biologics Co Ltd
Sandoz AG
Siegfried Holding AG
Tricida Inc
Vaccinex Inc
WuXi AppTec Co Ltd

Table of Contents

Table of Contents

1 Industry Trends

1.1 New FDA initiatives aim to modernize pharmaceutical manufacturing oversight

1.2 European drug manufacturers under threat from proposed US supply chain bill

1.3 Specialty vs. diversity: the four-way CDMO race in outsourced HPAPI manufacturing

1.4 Samsung biologics: geographic diversification is a sound business decision

2 Industry Analysis

2.1 Contract service agreements

2.2 Contract manufacturing – opportunities and threats

2.3 Quarterly mergers, acquisitions, and financing – Q3 2026

3 Value Chain

3.1 API chemical

3.2 API biologics – cell, gene, vaccine, and virus

3.3 API biologics – protein and peptide

3.4 Commercial dose manufacturing and packaging

3.5 Clinical dose manufacturing

3.6 Analytical services

4 About GlobalData

5 About the Authors

6 Contact Us

Table

Table 1: Contract service agreements

Table 2: Contract manufacturing: opportunities and threats – potentially positive

Table 3: Contract manufacturing: opportunities and threats – potentially negative

Table 4: Mergers, acquisitions, and financing – Q3 2026

Figures

Figure 1: Number of FDA-approved innovator and biosimilar drugs manufactured by geography

Figure 2: Number of HPAPIs outsourced by CDMO and containment type

Figure 3: Contract service agreements by deal geography, by volume

Figure 4: Deals by deal geography, by volume – mergers, acquisitions, and financing

Figure 5: The contract manufacturing value chain

Bio/Pharmaceutical Outsourcing Report, July 2026 standard reports
Currency USD
$2,950

Can be used by individual purchaser only

Most Popular
$5,900

Can be shared by unlimited users within one corporate location e.g. a regional office

$8,850

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

Bio/Pharmaceutical Outsourcing Report, July 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Contract Manufacturers reports
Pharmaceuticals
New
Rare Diseases: Innovation, Investment, and Unmet Needs - Strategic Intelligence
$3,450 | September 2026
Pharmaceuticals
New
Bio/Pharmaceutical Outsourcing Report, August 2026
$2,950 | September 2026
Pharmaceuticals
New
Small-Cell Lung Cancer (SCLC): Market View, Current and Future Competitive…
$3,495 | September 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bio/Pharmaceutical Outsourcing Report, July 2026 in real time.

  • Access a live Bio/Pharmaceutical Outsourcing Report, July 2026 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more